Short Interest in Zealand Pharma A/S (OTCMKTS:ZLDPF) Decreases By 31.8%

Zealand Pharma A/S (OTCMKTS:ZLDPF) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 1,388,200 shares, adecreaseof31.8% from the July 15th total of 2,034,900 shares. Approximately2.0% of the shares of the company are sold short. Based on an average daily volume of 600 shares, the short-interest ratio is presently 2,313.7 days. Based on an average daily volume of 600 shares, the short-interest ratio is presently 2,313.7 days. Approximately2.0% of the shares of the company are sold short.

Zealand Pharma A/S Price Performance

OTCMKTS:ZLDPF opened at $61.00 on Thursday. The company has a market cap of $4.33 billion, a PE ratio of 4.28 and a beta of 0.71. Zealand Pharma A/S has a twelve month low of $49.98 and a twelve month high of $136.76. The company has a current ratio of 25.10, a quick ratio of 25.07 and a debt-to-equity ratio of 0.03. The company’s 50 day moving average is $57.26 and its two-hundred day moving average is $70.28.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings data on Thursday, August 14th. The company reported $16.06 EPS for the quarter, missing the consensus estimate of $16.72 by ($0.66). The business had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $9.18 billion. Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 82.30%. Analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ZLDPF. Barclays raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Monday, July 7th. Wells Fargo & Company raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Thursday, July 24th. BNP Paribas raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Tuesday, July 1st. Finally, Zacks Research lowered shares of Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research report on Friday, August 15th. Five investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy”.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.